Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novo Nordisk (NVO) Owns 55% Of All Insulin Sales With A Patent Stretching To 2022; This Makes Them A Top Pick In Healthcare For The Chairman of Dividend Growth Advisors
Novo Nordisk (NVO) Owns 55% Of All Insulin Sales With A Patent Stretching To 2022; This Makes Them A Top Pick In Healthcare For The Chairman of Dividend Growth Advisors
Novo Nordisk (NVO) Owns 55% Of All Insulin Sales With A Patent Stretching To 2022; This Makes Them A Top Pick In Healthcare For The Chairman of Dividend Growth Advisors
Submitted by
admin
on December 14, 2011 - 11:02am
Source:
Yahoo/Wall St Transcript
News Tags:
diabetes
insulin
Novo Nordisk
Headline:
Novo Nordisk (NVO) Owns 55% Of All Insulin Sales With A Patent Stretching To 2022; This Makes Them A Top Pick In Healthcare For The Chairman of Dividend Growth Advisors
Do Not Allow Advertisers to Use My Personal information
